Biopharmaceuticals Industry Overview
|Study Period:||2018 - 2028|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Biopharmaceuticals Market Analysis
The biopharmaceuticals market is estimated to be USD 407.72 billion in the current year. It is expected to reach USD 651.78 billion by the end of the forecast period, registering a CAGR of 8.03%.
The COVID-19 pandemic had a significant impact on the biopharmaceutical industry. Most biopharmaceutical companies strived extensively for the development of vaccines against the SARS-CoV2 virus. For example, in April 2021, Mission COVID Suraksha was announced by the Government of India to accelerate the development and production of indigenous COVID vaccines, which was implemented by the Department of Biotechnology. The production capacity of Covaxin increased from 1 crore vaccine doses in April 2021 to 6-7 crore vaccine doses per month between July/August 2021. Also, it was expected to reach nearly 10 crore doses per month during September 2021. On the other hand, in June 2022, Pfizer announced its commitment to US manufacturing with a USD 120 million investment at its Kalamazoo (Michigan) facility, enabling United States-based production for its COVID-19 oral treatment, PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment represents yet another significant step in Pfizer's initiative to expand the amount of critical biopharmaceutical manufacturing in the United States, enhancing Pfizer's capacity to manufacture and provide treatments and medications for patients in the United States and around the world. Similarly, in August 2021, the Government of Canada announced an agreement with leading COVID-19 vaccine developer Moderna, Inc. to build an mRNA vaccine facility in Canada. The goals of the recently unveiled biomanufacturing and life science strategy were in line with Moderna's aspirations to build an mRNA vaccine manufacturing facility in Canada. The action was expected to improve Canada's overall industrial competence and boost the whole value chain of the biomanufacturing and life sciences industry, from talent acquisition and retention to greater clinical trial capacity. The increased interest in the manufacturing of COVID-19 vaccines is expected to have significantly added to the growth of the biopharmaceutical market during the COVID-19 pandemic.
Factors such as increasing acceptance of and huge market demand for biopharmaceuticals and ability of biopharmaceuticals to treat previously untreatable diseases are driving the growth of the market. As per the Alzheimer’s Association 2021 report, the United States Food and Drug Administration (FDA) approved five drugs for the treatment of Alzheimer’s, namely rivastigmine, galantamine, donepezil, memantine, and memantine, combined with donepezil. As per the same source, the vast majority of people who develop Alzheimer’s dementia are aged 65 years and above. This is called late-onset Alzheimer’s. In the United States, nearly 5.3% of people aged 65 to 74 years, 13.8% of people aged 75 to 84 years, and 34.6% of people aged 85 years or above have Alzheimer’s dementia. Additionally, an estimated 6.2 million Americans aged 65 years and above were living with Alzheimer’s dementia in 2021 and this number is projected to reach 13.5 million by 2050. Such a higher prevalence of the disease is anticipated to bolster the demand for API among the patient population over the coming years.The capability of biopharmaceutical products to address previously untreatable conditions has paved the way for the introduction of innovative drugs in the market. For instance, in September 2022, bluebird bio, Inc.’s SKYSONA (elivaldogene autotemcel), which is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD) was approved by CBER. Similarly, in June 2022, CBER approved PRIORIX, a live vaccine for measles, mumps, and rubella, manufactured by GSK plc. Also, in February 2022, Johnson and Johnson and its China-focused partner company Legend Biotech Corp developed a therapy to treat a type of white blood cell cancer, which was approved by the United States Food and Drug Administration (FDA). Such new therapies that aid in the treatment of oncologic disorders are expected to add to the market growth over the forecast period.
However, high-end manufacturing requirements and complicated and cumbersome regulatory requirements are expected to hinder market growth over the forecast period.
Biopharmaceuticals Industry Segments
As per the scope of the report, biopharmaceuticals refer to any biologically synthesized molecules used to treat or manage disorders. The Biopharmaceuticals Market is segmented By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell, Gene Therapies, Synthetic Immunomodulators, and Other Product Types), Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, and Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
|By Product Type|
|By Therapeutic Application|
|Inflammatory and Infectious Diseases|
|Other Therapeutic Applications|
Biopharmaceuticals Market Trends
This section covers the major market trends shaping the Biopharmaceuticals Market according to our research experts:
Monoclonal Antibodies is Expected to Witness High Growth Over the Forecast Period
Monoclonal antibodies (also called moAbs or mAbs) are proteins made in laboratories that behave like the antibodies in our systems. The successful use of monoclonal antibodies and antibody derivatives in therapeutics is the primary driver for the rapid growth of the studied segment. The therapeutic applications of monoclonal antibodies include cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases.
Growing approvals and clinical trials and increasing research expenditure are critical factors in this segment's growth. In October 2022, PT217, a bispecific anti-Delta-like ligand 3 (DLL3)/anti-Cluster of Differentiation 47 (CD47) antibody being developed by Phanes Therapeutics, Inc., a clinical-stage biotech company focused on oncology for patients with small cell lung cancer (SCLC) and other neuroendocrine cancers, received Phase 1 clearance by the US Food and Drug Administration (FDA). Additionally, the growing FDA approvals and new product launches for various indications are expected to drive the segment. For instance, in February 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 among adults and pediatric patients with a positive COVID-19 test, who are at a high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
Thus, owing to the aforementioned factors, the monoclonal antibodies segment is anticipated to witness significant growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Biopharmaceuticals Market
The growing burden of chronic diseases and increasing investments in research and development activities in the United States are the major factors driving the biopharmaceuticals market in North America. The US market for biopharmaceuticals is expected to grow due to factors such as increasing incidences of chronic diseases, the presence of well-established biopharmaceutical companies, and an increase in the number of biotech companies. The rising geriatric population and increased research and developments in the country also drive market growth.
In addition, the Centers for Disease Control and Prevention's (CDC) data updated in July 2022 shows that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older suffer from the ailment in the United States. Additionally, as per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack annually. Thus, the high burden of cardiovascular diseases demands the availability of advanced drugs for treatment.
In May 2022, Eli Lilly and Company announced an investment of USD 2.1 billion to expand its manufacturing footprint in Indiana, United States. Similarly, in May 2022, LOTTE purchased Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York. The East Syracuse site will serve as the LOTTE Center for North America Operations for LOTTE’s new biologics contract development and manufacturing organization (CDMO) business in the United States.
Thus, given the aforementioned factors, the studied market is expected to grow significantly in North America over the forecast period.
To understand geography trends, Download Sample Report
Biopharmaceuticals Market Competitor Analysis
The biopharmaceuticals market is fragmented in nature due to the presence of several companies operating. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well-known, including Amgen Inc., Eli Lily and Company, Johnson and Johnson, Sanofi SA, AstraZeneca PLC, and Pfizer Inc., among others.
Biopharmaceuticals Market Top Players
Bristol-Myers Squibb Company
Eli Lilly and Company
Johnson & Johnson
*Disclaimer: Major Players sorted in no particular order
Biopharmaceuticals Market Recent Developments
- August 2022: Amgen acquired ChemoCentryx, Inc., to treat autoimmune diseases, inflammatory disorders, and cancer, for USD 52 per share in cash, representing an enterprise value of approximately USD 3.7 billion.
- May 2022: LOTTE purchased Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York. The East Syracuse site will serve as the LOTTE Center for North America Operations for LOTTE’s new biologics contract development and manufacturing organization (CDMO) business in the United States.
- January 2022: Amgen collaborated with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
Biopharmaceuticals Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance of and Huge Market Demand for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.3 Market Restraints
4.3.1 High-end Manufacturing Requirements
4.3.2 Complicated and Cumbersome Regulatory Requirements
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product Type
5.1.1 Monoclonal Antibodies
184.108.40.206 Anti-cancer Monoclonal Antibodies
220.127.116.11 Anti-inflammatory Monoclonal Antibodies
18.104.22.168 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
22.214.171.124 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
126.96.36.199 Leukemia Inhibitory Factor (LIF)
188.8.131.52 P53 Protein
184.108.40.206 P38 Protein
220.127.116.11 Other Purified Proteins
5.1.4 Recombinant Proteins
18.104.22.168 Serum Albumin
22.214.171.124 Amyloid Protein
5.1.5 Recombinant Hormones
126.96.36.199 Recombinant Human Growth Hormones
188.8.131.52 Recombinant Insulin
184.108.40.206 Other Recombinant Hormones
220.127.116.11 Recombinant Vaccines
18.104.22.168.1 Cancer Vaccine
22.214.171.124.2 Malaria Vaccine
126.96.36.199.3 Ebola Vaccine
188.8.131.52.4 Hepatitis-B Vaccine
184.108.40.206.5 Tetanus Vaccine
220.127.116.11.6 Diptheria Vaccine
18.104.22.168.7 Cholera Vaccine
22.214.171.124.8 Other Recombinant Vaccines
126.96.36.199 Conventional Vaccines
188.8.131.52.1 Polio Vaccine
184.108.40.206.2 Pox Vaccine
220.127.116.11.3 Other Conventional Vaccines
5.1.7 Recombinant Enzymes
5.1.8 Cell and Gene Therapies
18.104.22.168 Allogenic Products
22.214.171.124 Autologous Products
126.96.36.199 Acellular Products
5.1.9 Synthetic Immunomodulators
188.8.131.52 Cytokines, Interferons, and Interleukins
5.1.10 Other Product Types
184.108.40.206 Blood Factors
220.127.116.11 Other Product Types
5.2 By Therapeutic Application
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Cardiovascular Diseases
5.2.7 Neurological Diseases
5.2.8 Other Therapeutic Applications
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lilly and Company
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk AS
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 F. Hoffmann-La Roche AG
6.1.11 Merck Co. & Inc.
6.1.12 Sanofi SA
6.1.13 AstraZeneca PLC
6.1.14 Bayer AG
6.1.15 Takeda Pharmaceutical Company Limited
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Biopharmaceuticals Market Research FAQs
What is the study period of this market?
The Biopharmaceuticals Market is studied from 2018 - 2028.
What is the growth rate of Biopharmaceuticals Market?
The Biopharmaceuticals Market is growing at a CAGR of 7.32% over the next 5 years.
What is Biopharmaceuticals Market size in 2018?
The Biopharmaceuticals Market is valued at 407 Billion USD in 2018.
What is Biopharmaceuticals Market size in 2028?
The Biopharmaceuticals Market is valued at 651 Billion USD in 2028.
Which region has highest growth rate in Biopharmaceuticals Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Biopharmaceuticals Market?
North America holds highest share in 2021.
Who are the key players in Biopharmaceuticals Market?
Amgen Inc., Abbvie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson are the major companies operating in Biopharmaceuticals Market.
Biopharmaceuticals Industry Reports
In-depth industry statistics and market share insights of the Biopharmaceuticals sector for 2020, 2021, and 2022. The Biopharmaceuticals research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Biopharmaceuticals report PDF.